Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for colorectal cancer: Choosing the right candidates

Expert Review of Anticancer Therapy

Volumn 15, Issue 8, 2015, Pages 859-861

  Larocca, Christopher J ^a   Tuttle, Todd M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

colorectal cancer; completeness of cytoreduction score; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; peritoneal cancer index

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DISEASE FREE INTERVAL; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; LAPAROSCOPY; MORBIDITY; PERITONEAL CANCER INDEX SCORE; PERITONEUM METASTASIS; RATING SCALE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; COLORECTAL NEOPLASMS; INTRAPERITONEAL DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATIENT SELECTION; PROCEDURES; THERMOTHERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CYTOREDUCTION SURGICAL PROCEDURES; HUMANS; HYPERTHERMIA, INDUCED; INJECTIONS, INTRAPERITONEAL; PATIENT SELECTION;

EID: 84937923162     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1069187     Document Type: Review

References (18)

1. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89(12):1545-50
2. Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012;99(5):699-705
3. van Gestel YR, Thomassen I, Lemmens VE, et al. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol 2014; 40(8):963-9
4. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88(2):358-63
5. Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2012;30(3):263-7
6. Klaver YL, Simkens LH, Lemmens VE, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol 2012;38(7): 617-23
7. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21(20):3737-43
8. Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15(9):2426-32
9. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27(5): 681-5
10. Chua TC, Esquivel J, Pelz JO, Morris DL. Summary of current therapeutic options for peritoneal metastases from colorectal cancer. J Surg Oncol 2013;107(6):566-73
11. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28(1):63-8
12. Jafari MD, Halabi WJ, Stamos MJ, et al. Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the American College of Surgeons National Surgical Quality Improvement Program. JAMA Surg 2014;149(2):170-5
13. Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004;85(2): 61-7
14. Elias D, Mariani A, Cloutier AS, et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 2014; 40(11):1467-73
15. Elias D, Honore C, Dumont F, et al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2011;254(2):289-93
16. Sammartino P, Sibio S, Biacchi D, et al. Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases. Int J Colorectal Dis 2014;29(9):1081-9
17. Polanco PM, Ding Y, Knox JM, et al. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies. Ann Surg Oncol 2015;22(5):1673-9
18. Kusamura S, Baratti D, Virzi S, et al. Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: analysis of two centres. J Surg Oncol 2013;107(4): 312-19